$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

$tsoi Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009468 Filed on March 29, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$23.12K	$8.580K	$206.8K
YoY Change	-72.76%	-80.57%	41.66%
Cost Of Revenue	$8.466K	$46.00K	$79.44K
YoY Change	-46.89%	207.69%	86.74%
Gross Profit	$14.66K	-$37.42K	$127.3K
YoY Change	-78.75%	-228.11%	23.12%
Gross Profit Margin	63.39%	-436.13%	61.58%
Selling, General & Admin	$391.8K	$457.2K	$1.766M
YoY Change	34.41%	36.05%	9.49%
% of Gross Profit	2673.13%		1387.08%
Research & Development	$52.73K	$264.0K	$1.441M
YoY Change	-82.66%	-56.8%	81.33%
% of Gross Profit	359.74%		1131.83%
Depreciation & Amortization	$2.720K	$49.96K	$10.95K
YoY Change	-60.29%	450.22%	-39.42%
% of Gross Profit	18.56%		8.6%
Operating Expenses	$444.5K	$721.2K	$3.207M
YoY Change	-25.37%	-23.86%	33.2%
Operating Profit	-$429.9K	-$758.6K	-$3.080M
YoY Change	-18.38%	-17.36%	33.66%
Interest Expense	$121.8K	-$70.40K	$646.1K
YoY Change	-264.1%	-82.56%	-198.44%
% of Operating Profit
Other Income/Expense, Net	-$148.0K	-$110.6K	-$597.1K
YoY Change	99.42%
Pretax Income	-$577.9K	-$939.7K	-$3.677M
YoY Change	-3.83%	-28.9%	24.2%
Income Tax		$0.00	$800.00
% Of Pretax Income
Net Earnings	-$577.9K	-$939.7K	-$3.678M
YoY Change	-3.83%	-28.95%	24.19%
Net Earnings / Revenue	-2499.16%	-10951.86%	-1778.72%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	2.734B shares	2.608B shares	2.528B shares
Diluted Shares Outstanding	2.692B shares		2.528B shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.53K	$18.04K	$18.04K
YoY Change	-88.82%	-80.82%	-80.82%
Cash & Equivalents	$18.53K	$18.04K	$18.04K
Short-Term Investments
Other Short-Term Assets	$128.5K	$223.4K	$223.4K
YoY Change	-81.64%	-76.96%	-76.96%
Inventory	$35.69K	$42.43K	$42.43K
Prepaid Expenses	$31.73K	$62.66K
Receivables	$17.73K	$25.40K	$25.40K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$200.5K	$309.2K	$309.2K
YoY Change	-78.71%	-72.39%	-72.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$270.4K	$273.1K	$281.7K
YoY Change	-13.01%	-3.85%	-11.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.935M	$3.015M	$11.66K
YoY Change	2900.18%	986.07%	-92.15%
Total Long-Term Assets	$3.349M	$3.296M	$3.296M
YoY Change	-12.77%	453.28%	453.28%
TOTAL ASSETS
Total Short-Term Assets	$200.5K	$309.2K	$309.2K
Total Long-Term Assets	$3.349M	$3.296M	$3.296M
Total Assets	$3.550M	$3.606M	$3.606M
YoY Change	-25.75%	110.14%	110.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$398.9K	$402.0K	$409.2K
YoY Change	7.11%	2.02%	3.85%
Accrued Expenses	$544.9K	$531.8K	$540.4K
YoY Change	5.97%	9.15%	5.43%
Deferred Revenue
YoY Change
Short-Term Debt	$1.056M	$1.054M	$1.054M
YoY Change	-1.68%	0.9%	0.9%
Long-Term Debt Due	$4.640K	$4.640K	$4.640K
YoY Change	0.0%	14.0%	14.0%
Total Short-Term Liabilities	$2.255M	$2.210M	$2.210M
YoY Change	-8.32%	-11.46%	-11.46%
LONG-TERM LIABILITIES
Long-Term Debt	$9.300K	$10.51K	$10.51K
YoY Change	-33.05%	-32.32%	-32.32%
Other Long-Term Liabilities	$120.1K	$0.00	$0.00
YoY Change	5486.51%	-100.0%	-100.0%
Total Long-Term Liabilities	$129.4K	$10.51K	$10.51K
YoY Change	706.8%	-56.82%	-56.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.255M	$2.210M	$2.210M
Total Long-Term Liabilities	$129.4K	$10.51K	$10.51K
Total Liabilities	$2.385M	$2.221M	$2.221M
YoY Change	-3.69%	-11.9%	-11.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.25M	-$17.67M
YoY Change		26.28%
Common Stock	$2.749M	$2.617M
YoY Change		13.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.165M	$1.385M	$1.385M
YoY Change
Total Liabilities & Shareholders Equity	$3.550M	$3.606M	$3.606M
YoY Change	-25.75%	110.14%	110.14%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$577.9K	-$939.7K	-$3.678M
YoY Change	-3.83%	-28.95%	24.19%
Depreciation, Depletion And Amortization	$2.720K	$49.96K	$10.95K
YoY Change	-60.29%	450.22%	-39.42%
Cash From Operating Activities	-$201.1K	-$365.1K	-$1.018M
YoY Change	-6.42%	142.03%	41.64%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$200.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$1.950K	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$1.951K	$200.0K
YoY Change	-100.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$445.0K
YoY Change			55.87%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$199.6K	88.86K	$943.1K
YoY Change	-58.97%	-51.34%	15.38%
NET CHANGE
Cash From Operating Activities	-$201.1K	-365.1K	-$1.018M
Cash From Investing Activities	$1.951K	200.0K
Cash From Financing Activities	$199.6K	88.86K	$943.1K
Net Change In Cash	$491.00	-76.20K	-$75.22K
YoY Change	-99.31%	-339.85%	-52.42%
FREE CASH FLOW
Cash From Operating Activities	-$201.1K	-$365.1K	-$1.018M
Capital Expenditures	$0.00	-$200.0K
Free Cash Flow	-$201.1K	-$165.1K	-$1.018M
YoY Change	-6.42%	9.43%	122.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001419051
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	TSOI	Shares To Be Issued SharesToBeIssued		usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	TSOI	Stock Issued During Period Value New Issues Preferred Stock StockIssuedDuringPeriodValueNewIssuesPreferredStock		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
CY2021	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-54554
CY2022	dei	Entity Registrant Name EntityRegistrantName	Therapeutic Solutions International, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1226465
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Wild Rose Lane
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Elk City
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	ID
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	83525
CY2022	dei	City Area Code CityAreaCode	760
CY2022	dei	Local Phone Number LocalPhoneNumber	295-7208
CY2022	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value per share
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1296570604	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2734250749	shares
CY2022	dei	Auditor Firm AuditorFirmId	5525
CY2022	dei	Auditor Name AuditorName	Fruci & Associates II, PLLC
CY2022	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18040	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94036	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	10223	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25398	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16613	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	42428	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	39817	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212352	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	959307	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	309221	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1119996	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	273078	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	284024	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8612	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34184	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3014620	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	277571	usd
CY2022Q4	us-gaap	Assets Assets	3605531	usd
CY2021Q4	us-gaap	Assets Assets	1715775	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	401992	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	394035	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	7209	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	9791	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	531783	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	487208	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8612	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25374	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4638	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4071	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	175063	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	225800	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	65187	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	79200	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	988672	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	965211	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202144	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	531525	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2210237	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2496415	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	10507	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	15532	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8810	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2220744	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2520757	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2617390830	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2617390830	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2311123860	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2311123860	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2617392	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2311125	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16334129	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10899139	usd
CY2022Q4	TSOI	Shares To Be Issued SharesToBeIssued	126324	usd
CY2022Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2021Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	21000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17672058	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13994246	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1384787	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-804982	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3605531	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1715775	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	206767	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	145956	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	79440	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	42544	usd
CY2022	us-gaap	Gross Profit GrossProfit	127327	usd
CY2021	us-gaap	Gross Profit GrossProfit	103412	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	491928	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	138710	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	444865	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	436555	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	432033	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	264540	usd
CY2022	us-gaap	Legal Fees LegalFees	397302	usd
CY2021	us-gaap	Legal Fees LegalFees	773203	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1441128	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	794750	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3207256	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2407758	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3079929	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2304346	usd
CY2022	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	131475	usd
CY2021	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	539006	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	291123	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	494501	usd
CY2022	us-gaap	Interest Expense InterestExpense	646089	usd
CY2021	us-gaap	Interest Expense InterestExpense	611794	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-110642	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-597083	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-656299	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3677012	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2960645	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3677812	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2961445	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2528062958	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2263126970	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1778099	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	858900	usd
CY2021	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	1472450	usd
CY2021	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	239799	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	285499	usd
CY2021	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	58900	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	529735	usd
CY2021	TSOI	Relief Of Derivative Liabilities ReliefOfDerivativeLiabilities	489279	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2961445	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-804982	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-804982	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	691520	usd
CY2022	TSOI	Stock Issued During Period Value For Prepaid Fees StockIssuedDuringPeriodValueForPrepaidFees	242320	usd
CY2022	TSOI	Stock Issued During Period Values For Salaries StockIssuedDuringPeriodValuesForSalaries	67399	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	445000	usd
CY2022	TSOI	Stock Issued During Period Value For License StockIssuedDuringPeriodValueForLicense	3107570	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1313772	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3677812	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1384787	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1384787	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3677812	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2961445	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	380820	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	397750	usd
CY2022	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties	310700	usd
CY2021	TSOI	Share Based Compensation To Related Parties ShareBasedCompensationToRelatedParties	461150	usd
CY2022	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	131475	usd
CY2021	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	539006	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	291123	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	494501	usd
CY2022	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	951748	usd
CY2021	TSOI	Amortization Of Prepaid Stock Based Compensation AmortizationOfPrepaidStockBasedCompensation	480135	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	593463	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	541612	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	233685	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11295	usd
CY2022	us-gaap	Depreciation Depreciation	10946	usd
CY2021	us-gaap	Depreciation Depreciation	6772	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8785	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14172	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2611	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	34418	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-174364	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-64777	usd
CY2022	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	25572	usd
CY2021	TSOI	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	24792	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15166	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	91557	usd
CY2022	TSOI	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	-9791	usd
CY2021	TSOI	Increase Decrease In Account Payable Related Parties IncreaseDecreaseInAccountPayableRelatedParties	2581	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	169451	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	188979	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-25572	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-24792	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1018304	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-718922	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	260565	usd
CY2021	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	4015	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-256550	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2453	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	4799	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	505000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	538750	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4459	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2068	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	445000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	285499	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	943088	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	817382	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-75216	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-158090	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104259	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	262349	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29043	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	104259	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3173	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3312	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	800	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	800	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	39000	usd
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	33500	usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	503726	usd
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	538750	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1313772	usd
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1019014	usd
CY2021	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	21671	usd
CY2022	TSOI	Common Stock Issued For Prepaid Fees Value CommonStockIssuedForPrepaidFeesValue	242320	usd
CY2021	TSOI	Common Stock Issued For Prepaid Fees Value CommonStockIssuedForPrepaidFeesValue	1472450	usd
CY2022	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	67399	usd
CY2021	TSOI	Common Stock Issued For Accrued Salaries Value CommonStockIssuedForAccruedSalariesValue	239799	usd
CY2022	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	25914	usd
CY2021	TSOI	Accrued Interest Added To Principal AccruedInterestAddedToPrincipal	25912	usd
CY2022	TSOI	Common Stock Issued For License Value CommonStockIssuedForLicenseValue	3107570	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	58900	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18040	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94036	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	11003	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	10223	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29043	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104259	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zHMMXb3Ty6i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_82D_zHl7RuiaS747">Organization and Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized <span id="xdx_902_edei--EntityIncorporationDateOfIncorporation_c20220101__20221231_zqhIZswywuqh" title="Entity incorporation date">August 6, 2007</span> under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Description</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cellular Division</b> – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On Augus<sup>t </sup>4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, <span id="xdx_900_eus-gaap--UnusualOrInfrequentItemNatureOfEventOrTransaction_c20210803__20210804_zAUCUWek9SM7" title="Unusual or infrequent item, description">the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Notes to Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not expect existing cash as of December 31, 2022 or as of March 31, 2023 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2022, the Company has incurred losses totaling $<span id="xdx_905_eus-gaap--ProfitLoss_pn5n6_c20220101__20221231_zTGm8Oxg81Kh" title="Net loss">17.3</span> million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2007-08-06
CY2021Q3	us-gaap	Unusual Or Infrequent Item Nature Of Event Or Transaction UnusualOrInfrequentItemNatureOfEventOrTransaction	the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.
CY2022	us-gaap	Profit Loss ProfitLoss	17300000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6807	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6807	usd
CY2022	TSOI	Wholesale Purchase Price And Payments Description WholesalePurchasePriceAndPaymentsDescription	Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2021Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202144	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	531525	usd
CY2020Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	437549	usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	1077756	usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	-489279	usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-494501	usd
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	531525	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	674971	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	-713229	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-291123	usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	202144	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zOZYgg1gZZTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zNo3hEJbYQF3">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	267136056	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	95273690	shares
CY2022	us-gaap	Depreciation Depreciation	10946	usd
CY2021	us-gaap	Depreciation Depreciation	6772	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	233685	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11295	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	27427	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	212352	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	959307	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	4132	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1441128	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	794750	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8612	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8612	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	10000	usd
CY2022	TSOI	Annual Interest Rate AnnualInterestRate	0.006	pure
CY2022	us-gaap	Restricted Cash Current Nature Of Restriction Description RestrictedCashCurrentNatureOfRestrictionDescription	This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.
CY2022Q4	TSOI	Prepaid Consulting Current PrepaidConsultingCurrent	148550	usd
CY2021Q4	TSOI	Prepaid Consulting Current PrepaidConsultingCurrent	930893	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1141	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	987	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	62661	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	301359	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	301159	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28281	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17135	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	273078	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	284024	usd
CY2022	us-gaap	Depreciation Depreciation	10946	usd
CY2021	us-gaap	Depreciation Depreciation	6772	usd
CY2022Q4	TSOI	Prepaid Consulting Noncurrent PrepaidConsultingNoncurrent	7537	usd
CY2021Q4	TSOI	Prepaid Consulting Noncurrent PrepaidConsultingNoncurrent	108673	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4123	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	39823	usd
CY2022Q4	TSOI	Licenses Noncurrent LicensesNoncurrent	3002960	usd
CY2021Q4	TSOI	Licenses Noncurrent LicensesNoncurrent	129075	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3014620	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	277571	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3261122	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	153552	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	258162	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	24477	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3002960	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	129075	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	233685	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	24477	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	988672	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	965211	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	988672	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	965211	usd
CY2022	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.005	pure
CY2022Q4	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	97	usd
CY2021Q4	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	101	usd
CY2022	TSOI	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax And State And Local Income Taxes Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxAndStateAndLocalIncomeTaxesRate	0.30	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-709666	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-621735	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-101347	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	168	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	405376	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	404872	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-71992	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-406437	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P36M
CY2022	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-04-30
CY2022	us-gaap	Payments For Rent PaymentsForRent	25044	usd
CY2021	us-gaap	Payments For Rent PaymentsForRent	22768	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2022Q4	us-gaap	Area Of Land AreaOfLand	1700	sqft
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-289487	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2364249	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1957812	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2364249	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1957812	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	9400000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	7500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	7400000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	5500000	usd
CY2022	TSOI	Net Operating Loss Carryforwards Are Available To Offset Taxable Income NetOperatingLossCarryforwardsAreAvailableToOffsetTaxableIncome	5000000	usd
CY2022	TSOI	Net Operating Loss Carryforwards Expiration Description NetOperatingLossCarryforwardsExpirationDescription	expires beginning in fiscal 2032
CY2022Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	3505000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3500000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2617390830	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2	shares
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8612	usd

Files In Submission

Name	View Source	Status
0001493152-23-009468-index-headers.html	Edgar Link	pending
0001493152-23-009468-index.html	Edgar Link	pending
0001493152-23-009468.txt	Edgar Link	pending
0001493152-23-009468-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsoi-20221231.xsd	Edgar Link	pending
tsoi-20221231_def.xml	Edgar Link	unprocessable
tsoi-20221231_cal.xml	Edgar Link	unprocessable
tsoi-20221231_lab.xml	Edgar Link	unprocessable
tsoi-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2023 Q1 Form 10-K Financial Statement

#000149315223009468 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi

2023 Q1 Form 10-K Financial Statement

#000149315223009468 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSOI
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Stock $tsoi